Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Acrivon Therapeutics, Inc. ( (ACRV) ) is now available.
On February 27, 2026, Acrivon Therapeutics hosted a live, company-sponsored key opinion leader panel during the ESGO Congress in Copenhagen to discuss interim Phase 2b data from its registrational-intent ACR-368 trial in endometrial cancer. Experts reviewed the study’s biomarker-driven design using the OncoSignature test, which prospectively selects patients based on CHK1/2 dependency, and highlighted the drug’s potential to address significant unmet need in high-grade and serous endometrial carcinoma.
The interim data presented showed notable objective response rates in biomarker-positive patients treated with ACR-368, including higher responses in those with two or fewer prior lines of therapy and meaningful disease control in serous and non-serous subgroups. Safety findings indicated a manageable toxicity profile consistent with chemotherapy-like hematologic adverse events, suggesting ACR-368 could strengthen Acrivon’s position in advanced gynecologic oncology and may offer a new option for heavily pretreated endometrial cancer patients, particularly after platinum and immunotherapy failure.
The most recent analyst rating on (ACRV) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.
Spark’s Take on ACRV Stock
According to Spark, TipRanks’ AI Analyst, ACRV is a Neutral.
The score is held down primarily by weak financial performance—no revenue, large and persistent losses, and substantial cash burn—despite low leverage. Technicals remain soft with the stock below key short- and mid-term moving averages, while valuation support is limited due to losses and no dividend. Offsetting these risks, recent positive clinical data and pipeline progress modestly improve the outlook.
To see Spark’s full report on ACRV stock, click here.
More about Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. is a clinical-stage oncology company developing targeted cancer therapies, including the CHK1/2 inhibitor ACR-368, guided by its proprietary OncoSignature biomarker platform. The company focuses on tumor-agnostic, functionally selected patient populations, with a particular emphasis on difficult-to-treat gynecologic malignancies such as high-grade endometrial cancer.
Average Trading Volume: 1,620,142
Technical Sentiment Signal: Sell
Current Market Cap: $47.33M
Find detailed analytics on ACRV stock on TipRanks’ Stock Analysis page.